CA3087943A1 - Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators - Google Patents

Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators Download PDF

Info

Publication number
CA3087943A1
CA3087943A1 CA3087943A CA3087943A CA3087943A1 CA 3087943 A1 CA3087943 A1 CA 3087943A1 CA 3087943 A CA3087943 A CA 3087943A CA 3087943 A CA3087943 A CA 3087943A CA 3087943 A1 CA3087943 A1 CA 3087943A1
Authority
CA
Canada
Prior art keywords
formula
compound
salt
base
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3087943A
Other languages
English (en)
French (fr)
Inventor
Debra Jane Wallace
Fenger ZHOU
Yuguang Wang
Takashi Nakai
Vishnu Vardhan Reddy Karnati
Wayne C. Schairer
William KISSEL
Song Xue
Ahmad Hashash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclerion Therapeutics Inc
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2018/076982 external-priority patent/WO2019161534A1/en
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of CA3087943A1 publication Critical patent/CA3087943A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3087943A 2018-01-10 2019-01-10 Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators Pending CA3087943A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862615678P 2018-01-10 2018-01-10
US62/615,678 2018-01-10
PCT/CN2018/076982 WO2019161534A1 (en) 2018-02-22 2018-02-22 Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators
CNPCT/CN2018/076982 2018-02-22
PCT/US2019/013060 WO2019140095A1 (en) 2018-01-10 2019-01-10 Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators

Publications (1)

Publication Number Publication Date
CA3087943A1 true CA3087943A1 (en) 2019-07-18

Family

ID=65279655

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3087943A Pending CA3087943A1 (en) 2018-01-10 2019-01-10 Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators

Country Status (17)

Country Link
US (5) US11274096B2 (https=)
EP (3) EP4249469A3 (https=)
JP (2) JP7357621B2 (https=)
KR (3) KR102739727B1 (https=)
CN (3) CN118221665A (https=)
AU (3) AU2019206560B2 (https=)
BR (1) BR112020013985A2 (https=)
CA (1) CA3087943A1 (https=)
CL (3) CL2020001814A1 (https=)
ES (1) ES2963447T3 (https=)
IL (3) IL275748B2 (https=)
JO (1) JOP20200165A1 (https=)
MA (2) MA71753A (https=)
MX (3) MX2020007364A (https=)
SG (1) SG11202006311SA (https=)
TW (2) TWI888947B (https=)
WO (1) WO2019140095A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563077B (zh) 2016-07-07 2026-03-10 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的新方法
MA71753A (fr) 2018-01-10 2025-05-30 Cyclerion Therapeutics, Inc. Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble
EP4640676A1 (en) * 2022-12-21 2025-10-29 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof
AU2023412238A1 (en) * 2022-12-21 2025-07-03 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR088020A1 (es) * 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc Compuestos heterociclicos como estimuladores de sgc
SI2970243T1 (sl) * 2013-03-15 2020-04-30 Cyclerion Therapeutics, Inc. SGC stimulatorji
WO2015106268A1 (en) * 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
KR20170055531A (ko) * 2014-09-17 2017-05-19 아이언우드 파마슈티컬스, 인코포레이티드 에스지씨 자극제
CA3006746C (en) * 2015-11-30 2024-01-30 Ironwood Pharmaceuticals, Inc. Solid dispersions comprising a sgc stimulator
CN109563077B (zh) 2016-07-07 2026-03-10 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的新方法
WO2018009602A2 (en) 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Novel processes for preparation of soluble guanylate cyclase stimulators
MA71753A (fr) 2018-01-10 2025-05-30 Cyclerion Therapeutics, Inc. Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble

Also Published As

Publication number Publication date
KR20250048609A (ko) 2025-04-09
TW201932450A (zh) 2019-08-16
US20220024909A1 (en) 2022-01-27
KR20250002720A (ko) 2025-01-07
AU2019206560B2 (en) 2023-08-24
SG11202006311SA (en) 2020-07-29
EP3737679C0 (en) 2023-09-06
IL275748A (en) 2020-08-31
IL314714A (en) 2024-10-01
AU2023270260B2 (en) 2026-01-29
EP3737679B1 (en) 2023-09-06
KR102739727B1 (ko) 2024-12-05
CN118184645A (zh) 2024-06-14
MX2023000045A (es) 2023-02-01
EP3737679A1 (en) 2020-11-18
MX2023000044A (es) 2023-02-01
KR20200106920A (ko) 2020-09-15
CN111902410A (zh) 2020-11-06
CN118221665A (zh) 2024-06-21
EP4570797A2 (en) 2025-06-18
US12275724B2 (en) 2025-04-15
BR112020013985A2 (pt) 2020-12-01
US20250361228A1 (en) 2025-11-27
US11708361B2 (en) 2023-07-25
EP4570797A3 (en) 2025-09-03
AU2025202281A9 (en) 2025-05-15
AU2019206560A1 (en) 2020-07-30
US20230339928A1 (en) 2023-10-26
MX2020007364A (es) 2020-11-18
TWI888947B (zh) 2025-07-01
AU2023270260A1 (en) 2023-12-07
EP4249469A3 (en) 2023-12-27
US12030874B2 (en) 2024-07-09
JP2021511299A (ja) 2021-05-06
AU2025202281A1 (en) 2025-04-17
JP7357621B2 (ja) 2023-10-06
JP7744955B2 (ja) 2025-09-26
US20240391911A1 (en) 2024-11-28
MA51565A (fr) 2020-11-18
IL275748B2 (en) 2025-01-01
CL2020001814A1 (es) 2020-11-06
TWI821237B (zh) 2023-11-11
WO2019140095A8 (en) 2020-06-18
US11274096B2 (en) 2022-03-15
CN111902410B (zh) 2024-04-19
CL2022000907A1 (es) 2022-10-21
ES2963447T3 (es) 2024-03-27
IL275748B1 (en) 2024-09-01
EP4249469A2 (en) 2023-09-27
JP2023182647A (ja) 2023-12-26
TW202402741A (zh) 2024-01-16
MA71753A (fr) 2025-05-30
CL2022000904A1 (es) 2022-10-21
WO2019140095A1 (en) 2019-07-18
US20210053962A1 (en) 2021-02-25
JOP20200165A1 (ar) 2022-10-30
IL319883A (en) 2025-05-01

Similar Documents

Publication Publication Date Title
JP7744955B2 (ja) 可溶性グアニル酸シクラーゼ刺激剤を調製するための新規のプロセスおよび中間体
HK40103207A (en) Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
HK40031722A (en) Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
HK40031722B (en) Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
EA045335B1 (ru) Новые способы и промежуточные соединения для получения стимуляторов растворимой гуанилатциклазы
EA048211B1 (ru) Новые способы и промежуточные соединения для получения стимуляторов растворимой гуанилатциклазы
WO2019161534A1 (en) Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators
EA052114B1 (ru) Новые способы и промежуточные соединения для получения стимуляторов растворимой гуанилатциклазы
WO2016071380A1 (en) Synthesis of pi3k inhibitor and salts thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240109

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250103

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250103

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250103

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250206

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250604

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250605

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250725

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250725

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260102

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260102

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260303